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Vascular endothelial cell growth factor (VEGF)-C levels were significantly (Po0.05) increased in 24 out of 40 metastatic lymph node
lesions of uterine cervical cancers. The prognosis of the 24 patients with increased VEGF-C level in metastatic lymph node lesions was
poor and the 24-month survival rate was 38%, while the rate of the 16 patients with no change in VEGF-C level in metastatic lymph
node lesions was 81%. There was a significant (Po0.01) difference in the 24-month survival rates between the two groups. This is
novel, direct evidence that VEGF-C might contribute to the aggressive lymphangitic metastasis in uterine cervical cancers, and that the
increase in VEGF-C level from primary tumour to metastatic lymph node might be a prognostic indicator.
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The presence of lymph node metastasis, recognised as the most
common metastatic lesion, is critical to patient prognosis in
uterine cervical cancers (Saigo et al, 1986; Noguchi et al, 1987,
Robert et al, 1990; Chen et al, 1998). Vascular endothelial cell
growth factor (VEGF)-C was cloned as a ligand of the Flt-4
(VEGFR-3) and KDR/flk-1 (VEGFR-2) receptor tyrosine kinases
and recognised as a novel VEGF (Joukov et al, 1996; Lee et al,
1996). VEGF-C induces selective hyperplasia of the lymphatic
vasculature, which is involved in the draining of interstitial fluid
and in immune function, inflammation, and tumour metastasis
(Jeltsch et al, 1997). Moreover, VEGF-C-induced lymphangiogen-
esis mediates tumour cell dissemination and the formation of
lymph node metastases in transgenic mice with VEGF-C expres-
sion (Mandriota et al, 2001). The expression of VEGF-C in
prostatic carcinoma cells has been implicated in lymph node
metastasis (Tsurusaki et al, 1999). Gastric cancer cells producing
VEGF-C induce the proliferation and dilation of lymphatic vessels,
resulting in the invasion of cancer cells into the lymphatic vessels
and lymph node metastasis (Yonemura et al, 1999), and the
lymphatic invasion was significantly increased in VEGF-C-positive
early gastric carcinoma (Kabashima et al, 2001). VEGF-C is
involved in the progression of human gastric carcinoma,
particularly via lymphangiogenesis, and VEGF-C expression at
the invading edge of a gastric carcinoma is a sensitive marker for
metastasis to the lymph nodes (Amioka et al, 2002). VEGF-C has
an important role in lymph node metastasis of breast cancer even
at its hormone-dependent early stage (Mattila et al, 2002).
Proliferating lymphatics can occur in head and neck cancers and
may in some cases contribute to lymph node metastasis (Beasley
et al, 2002). The involvement of VEGF-C expression in the
promotion of lymph node metastasis in cervical cancer has been
demonstrated. Furthermore, examination of VEGF-C expression in
biopsy specimens may be beneficial in the prediction of pelvic
lymph node metastasis (Hashimoto et al, 2001).
Although lymph node metastasis has been analysed by the
manner of VEGF-C expression in primary tumours, the VEGF-C
expression status in metastatic lymph nodes as a result has not
been directly investigated. This status prompted us to investigate
the clinical significance of VEGF-C expressed in lymph nodal
metastasis of uterine cervical cancers.
MATERIALS AND METHODS
Patients
Consent for the following studies was obtained from all patients
and the Research Committee for Human Subjects, Gifu University
School of Medicine. A total of 40 patients ranging from 39 to 82
years of age underwent curative resection for cervical cancer stage
IIb. All cases involved direct extension to the parametrium
histopathologically, and had lymph node metastasis. The tumour
diameters are shown in Figure 1. The therapy after operation was
whole pelvic irradiation covering the lymph node areas for all
cases. Their 24-month survival rates were assessed at the
Department of Obstetrics and Gynecology, Gifu University School
of Medicine, between January 2000 and March 2002. None of the
patients had received any preoperative therapy. A part of each
tissue of uterine cervical cancers was obtained immediately after
hysterectomy and was snap-frozen in liquid nitrogen to determine
the levels of VEGF-C, and a neighbouring part of the tissues was
submitted for histopathological study. Perfect lymphadenectomy
was performed with ease, and all lymph nodes taken were divided
into two; one piece was used for histopathological examination and
immunohistochemical staining, and the other was used for enzyme
immunoassay. The clinical stage of uterine cervical cancers was
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ldetermined by International Federation of Obstetrics and Gyne-
cology (FIGO) classification (FIGO News, 1989).
Immunohistochemistry
Sections (4mm) of formalin-fixed paraffin-embedded tissues were
cut with a microtome and dried overnight at 371C on a silanised-
slide (Dako, Carpinteria, USA). Samples were deparaffinised in
xylene at room temperature for 80min and washed with a graded
ethanol/water mixture and then with distilled water. The samples
for VEGF-C antigen were soaked in citrate buffer (10mM citrate),
microwaved for 10min, and then treated with 3% H2O2 in a
phosphate buffer (PBS) at room temperature for 20min. The
protocol for a DAKO LSAB2 Kit, Peroxidase (Dako) was followed
for each sample except for the incubation condition for the first
antibody. Goat anti-human VEGF-C (200mgml
 1, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was used at a dilution of
1:50 as the first antibody with incubation at 41C overnight. The
addition of the first antibody, goat anti-human VEGF-C, was
omitted in the protocols for negative controls of VEGF-C.
The results of immunohistochemical staining for VEGF-C were
semiquantitatively evaluated as described by McCarty et al (1985).
The evaluations were recorded as the percentage of positive-
stained cells in each of five intensity categories that were denoted
as 0, 1, 2, 3, 4, and 5. Each stained section was given a
histochemical score (histoscore, HS) calculated by the formula: S
(iþ1)   Pi, in which i¼cellular staining intensity (range 1–4, 0
indicates no staining) and Pi¼percentage of stained cells.
Enzyme immunoassay for determination of human VEGF-
C antigen
All steps were carried out at 41C. Tissues (wet weight, 10–20mg)
were homogenised in HG buffer (5mM Tris-HCl, pH 7.4, 5mM
NaCl, 1mM CaCl2,2 m M ethyleneglycol-bis-[b-aminoethyl ether]-
N,N,N0,N0-tetraacetic acid, 1mM MgCl2,2 m M dithiothreitol,
25mgml
 1 aprotinin, and 25mgml
 1 leupeptin) with a Polytron
homogeniser (Kinematics, Luzern, Switzerland). This suspension
was centrifuged in a microfuge at 10000g for 3min to obtain the
supernatant. The protein concentration of samples was measured
by the method of Bradford (1976) to standardise VEGF-C antigen
levels.
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Figure 1 Tumour diameter of all cases. Alive and deceased cases are
numbered in J and K, respectively.
Figure 2 Immunohistochemical staining for VEGF-C in primary tumour
and metastatic lymph node lesion in a representative case of uterine
cervical cancer (original magnification  200). A case of large cell
nonkeratinising squamous cell carcinoma of the uterine cervix, metastatic
lesion in cardinal lymph nodes. The addition of the first antibody, goat anti-
human VEGF-C antibody, was omitted in the protocols for negative
controls of VEGF-C.
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Figure 3 VEGF-C histoscores in primary tumour and in metastatic lymph
node lesion of uterine cervical cancers. VEGF-C histoscores were
determined as described in Materials and methods. In the primary tumours
and corresponding metastatic lymph node lesions, alive and deceased cases
are numbered in J and K, respectively. Bold lines, increased significantly
(Po 0.05 vs each primary tumour) from the primary tumour to the
corresponding metastatic lymph node lesion. Broken lines, no significant
change between the primary tumour and the corresponding metastatic
lymph node lesion.
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ELISA kit (MBL, Nagoya, Japan). The levels of VEGF-C were
standardised with the corresponding cellular protein concen-
trations.
Statistics
The 24-month survival rate was calculated according to the
Kaplan–Meier method and analysed by the log-rank test. VEGF-C
histoscores and levels were measured from three parts of the same
tissue in triplicate. Statistical analysis was performed with a paired
t-test. Differences were considered significant when P-value was
less than 0.05.
RESULTS
Immunohistochemical staining for VEGF-C in a representative
case of large cell nonkeratinising squamous cell carcinoma is
shown in Figure 2. VEGF-C was dominantly distributed in the
cancer cells. As shown in Figure 3, VEGF-C histoscores in 24 out of
40 metastatic lymph node lesions of uterine cervical cancers
(shown with bold lines) were significantly (Po0.05) higher than in
the corresponding primary tumours, while the scores in the other
16 lesions (shown with broken lines) were not significantly altered.
The VEGF-C level in the primary tumours was less than
approximately 300pgmg
 1 protein (Figure 4). On the other hand,
the VEGF-C level in 24 out of 40 metastatic lymph node lesions of
uterine cervical cancers (shown with bold lines) was remarkably
(Po0.05) higher than in the corresponding primary tumours,
while the level in the other 16 lesions (shown with broken lines)
was not significantly altered. The cases with increased VEGF-C as
identified by immunohistochemical staining were the same cases
as those identified by the ELISA (Figures 3 and 4). The VEGF-C
levels significantly (Po0.001) correlated with the VEGF-C histo-
scores as shown in Figure 5.
The prognosis of the 24 patients with increased VEGF-C level in
the metastatic lesions was poor and the 24-month survival rate was
38% (9 of 24), while the rate of the other 16 patients with
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Figure 4 VEGF-C levels in primary tumour and metastatic lymph node
lesions of uterine cervical cancers. VEGF-C levels were determined using a
VEGF-C ELISA kit (MBL, Nagoya, Japan). Each level is the mean7s.d. of
nine determinations from three parts of the same tissue in triplicate. In the
primary tumours and the corresponding metastatic lymph node lesions,
alive and deceased cases are numbered in J and K, respectively. Bold
lines, increased significantly (Po0.05 vs each primary tumour) from the
primary tumour to the corresponding metastatic lymph node lesion.
Broken lines, no change between the primary tumour and the
corresponding metastatic lymph node lesion.
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Figure 5 Correlation between VEGF-C levels and VEGF-C histoscores
in primary tumour and metastatic lymph node lesions of uterine cervical
cancers. Alive and deceased cases in the primary tumours are numbered in
J and K, respectively. Alive and deceased cases in the metastatic lymph
nodes are numbered in & and ’, respectively.
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Figure 6 Survival rate after curative resection for uterine cervical
cancers. Patient prognosis was analysed with a 24-month survival rate.
Increased, the cases with significantly increased VEGF-C level from the
primary tumour to the metastatic lymph node lesion; not increased, the
cases with no change in VEGF-C level from the primary tumour to the
metastatic lymph node lesion.
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There was a significant (Po0.01) difference in the 24-month
survival rates between the two groups (Figure 6).
DISCUSSION
In the present study, the VEGF-C level in 24 out of 40 metastatic
lymph node lesions of uterine cervical cancers was remarkably
increased, and the prognosis of the 24 patients was poor. Many
authors have reported that VEGF-C contributes to lymphogenous
metastasis. If indeed it does, a cancer cell enriched with VEGF-C in
the cancer tissue may selectively work on lymphogenous
metastasis, and the expression of VEGF-C would be increased
from the primary tumour to the corresponding metastatic lymph
node lesions. Furthermore, such a phenomenon would be induced
in a cascade manner, causing VEGF-C expression to be increased
in the secondary metastatic lymph node lesions, resulting in poor
clinical prognosis in such cases. On the other hand, in the cases
with no change in the VEGF-C level, VEGF-C might not mainly or
directly contribute to lymph node metastasis. Although lymph
node metastasis appears to be regulated by additional factors
besides VEGF-C, such a cascade of lymph node metastasis might
be less active in these cases, resulting in comparatively better
patient prognosis. This is novel, direct evidence that VEGF-C
might contribute to aggressive lymphangitic metastasis, and that
the increase in VEGF-C level from primary tumour to metastatic
lymph nodes might be a prognostic indicator. Therefore, VEGF-C
might be a key signal to evoke and maintain the cascade of lymph
node metastasis, and may be useful as a tumour marker for patient
prognosis and a molecular target for treatment.
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